Venaxis Board Appoints Senior Diagnostics Executive to Board of Directors
CASTLE ROCK, Colo., Dec. 20, 2012
CASTLE ROCK, Colo., Dec. 20, 2012 /PRNewswire/ --Venaxis, Inc. (Nasdaq:
APPY), an in vitro diagnostic company, today announced the appointment of
Susan A. Evans, Ph.D., FACB, Vice President, Scientific Affairs for Beckman
Coulter, to the Company's Board of Directors effective January 1, 2013. Dr.
Evans, a 30-year veteran of the in vitro diagnostics industry, has developed
numerous successful diagnostic tests over the course of her career. In
addition, she is highly respected within the industry, as evidenced by her
past selection as President of the American Association of Clinical Chemistry
(AACC), one of the industry's lead professional organizations. Dr. Evan's
experience will greatly benefit Venaxis as the company completes the
development and regulatory clearance for and executes the launch of APPY1, and
enhances its product portfolio.
Steve Lundy, President and CEO of Venaxis, stated, "We are excited to welcome
Dr. Evans to our Board. We expect 2013 to be a transformational year for
Venaxis and Dr. Evans' experience developing and launching in vitro diagnostic
products will be very beneficial as we develop the market for APPY1 and look
to develop next generation assays."
Dr. Evans stated, "I believe APPY1 potentially fulfills a significant
diagnostic need for emergency room physicians who are concerned about the
safety risks and cost associated with current imaging techniques. I am happy
to join the Venaxis Board of Directors and look forward to supporting the
commercialization of this important diagnostic test and further developing the
Venaxis product line."
Susan A. Evans, Ph.D., FACB brings 30 years of experience in diagnostics and
laboratory medicine. She serves currently as Vice President, Scientific
Affairs for the Beckman Coulter division of Danaher Inc. Dr. Evans has been
with Beckman Coulter since 2006, where she held past roles as Vice President,
Corporate Strategic Planning and Vice President/General Manager of Beckman
Coulter Genomics, known formerly as Agencourt Bioscience. Prior to her career
at Beckman Coulter, Dr. Evans held senior product development and R&D
positions at Caliper Life Sciences and LifeScan, respectively. Dr. Evans
began her career in diagnostics at Dade Behring, Inc., where she served in
various R&D capacities from 1981 – 2000, eventually assuming a leadership role
as Senior Vice President of R&D. Dr. Evans is also a Past President,
Secretary, and member of Board of Directors for the American Association of
Clinical Chemistry (AACC), for which she received an award in 2008 for
outstanding contributions through service to the profession. She currently
Chairs the Van Slyke Foundation Board of Trustees as well as the Awards
Committee for AACC. Dr. Evans earned a Ph.D. in chemistry from the University
About Venaxis, Inc.
Venaxis, Inc. (formerly known as AspenBio Pharma, Inc.) is an in vitro
diagnostic company focused on the clinical development and commercialization
of its blood-based appendicitis test, APPY1. The unique appendicitis test has
projected high sensitivity and negative predictive value and is designed to
aid in the identification of patients at low risk for acute appendicitis,
allowing for more conservative patient management. APPY1 is being developed
initially for pediatric, adolescent and young adult patients with abdominal
pain, as this population is at the highest risk for appendicitis and has the
highest risk of long-term health effects associated with CT imaging. For more
information, visit www.venaxis.com.
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in this press
release that address activities, events or developments that Venaxis believes
or anticipates will or may occur in the future are forward-looking statements.
These statements are based on certain assumptions made based on experience,
expected future developments and other factors Venaxis believes are
appropriate in the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the control of
Venaxis. Investors are cautioned that any such statements are not guarantees
of future performance. Actual results or developments may differ materially
from those projected in the forward-looking statements as a result of many
factors, including our ability to successfully complete required product
development and modifications in a timely and cost effective manner, complete
clinical trial activities for APPY1 required for FDA submission, obtain FDA
clearance or approval, complete and obtain CE Mark, cost effectively
manufacture and generate revenues from APPY1, execute agreements required to
successfully advance the company's objectives, retain the management team to
advance the products, overcome adverse changes in market conditions and the
regulatory environment, obtain and enforce intellectual property rights, and
realize value of intangible assets. Furthermore, Venaxis does not intend (and
is not obligated) to update publicly any forward-looking statements. The
contents of this press release should be considered in conjunction with the
risk factors contained in Venaxis' recent filings with the SEC, including its
Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.
For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
SOURCE Venaxis, Inc.
Press spacebar to pause and continue. Press esc to stop.